Real-world data of autologous stem cell transplantation for patients with mantle cell lymphoma in Argentina

IF 1.6 Q3 HEMATOLOGY

Hematology, Transfusion and Cell Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-02 DOI:10.1016/j.htct.2026.106449

Martín Milanesio , Mariano Berro , Adriana Vitriu , María Sol Jarchum , Silvina Palmer , Amalia Cerutti , Evelyn Colombo , Malena Rocca , Lautaro Sardu , Ana Laura Romero , Micaela Quarchioni , Fernando Warley , Alejandra Banchieri , Germán Wernicke , María Marta Rivas , José Trucco , Leandro Castellanos , Luciana Guanchiale , Ana Romina Montivero , Cecilia Foncuberta , Ana Lisa Basquiera

{"title":"Real-world data of autologous stem cell transplantation for patients with mantle cell lymphoma in Argentina","authors":"Martín Milanesio , Mariano Berro , Adriana Vitriu , María Sol Jarchum , Silvina Palmer , Amalia Cerutti , Evelyn Colombo , Malena Rocca , Lautaro Sardu , Ana Laura Romero , Micaela Quarchioni , Fernando Warley , Alejandra Banchieri , Germán Wernicke , María Marta Rivas , José Trucco , Leandro Castellanos , Luciana Guanchiale , Ana Romina Montivero , Cecilia Foncuberta , Ana Lisa Basquiera","doi":"10.1016/j.htct.2026.106449","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>For eligible patients with mantle cell lymphoma who respond to induction therapy, first-line consolidation with autologous hematopoietic progenitor cell transplantation remains a standard treatment. However, outcomes for these patients in Argentina have not been fully characterized. This paper aims to describe the factors linked to improved survival of patients with mantle cell lymphoma after transplantation in Argentina. In addition, the association between relapse within the first 24 months after transplant and overall survival was evaluated.</div></div><div><h3>Methods</h3><div>A retrospective, multicenter study was carried out. Patients over 18 years of age with a diagnosis of mantle cell lymphoma who received autologous hematopoietic progenitor cell transplantation from 2007–2023 at centers affiliated with the Argentine Group for Bone Marrow Transplantation and Cellular Therapy (GATMO-TC) were included. For the survival analysis, a landmark approach was utilized: overall survival was calculated from the date of progression for the group that relapsed within 24 months, and from the 24-month post-transplantation landmark for those who did not.</div></div><div><h3>Results</h3><div>One hundred and sixty-six patients from nine Argentine centers were included, 128 of whom were men (77%). The median age at transplantation was 58 years. Eighteen (11%) had blastoid morphology. The pretransplant status was complete response in 145 (87%) patients. With a median follow-up of 38.4 months, the median overall survival and progression-free survival were 102 and 48.8 months, respectively. In the multivariate analysis, the blastoid variant, an age ≥55 years, and a transplant comorbidity index ≥2 were independent predictors of survival.</div></div><div><h3>Conclusions</h3><div>>70% achieved prolonged survival. Blastoid morphology, age older than 55 years, and comorbidities diminished outcomes after transplantation.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 2","pages":"Article 106449"},"PeriodicalIF":1.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137926001963","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

For eligible patients with mantle cell lymphoma who respond to induction therapy, first-line consolidation with autologous hematopoietic progenitor cell transplantation remains a standard treatment. However, outcomes for these patients in Argentina have not been fully characterized. This paper aims to describe the factors linked to improved survival of patients with mantle cell lymphoma after transplantation in Argentina. In addition, the association between relapse within the first 24 months after transplant and overall survival was evaluated.

Methods

A retrospective, multicenter study was carried out. Patients over 18 years of age with a diagnosis of mantle cell lymphoma who received autologous hematopoietic progenitor cell transplantation from 2007–2023 at centers affiliated with the Argentine Group for Bone Marrow Transplantation and Cellular Therapy (GATMO-TC) were included. For the survival analysis, a landmark approach was utilized: overall survival was calculated from the date of progression for the group that relapsed within 24 months, and from the 24-month post-transplantation landmark for those who did not.

Results

One hundred and sixty-six patients from nine Argentine centers were included, 128 of whom were men (77%). The median age at transplantation was 58 years. Eighteen (11%) had blastoid morphology. The pretransplant status was complete response in 145 (87%) patients. With a median follow-up of 38.4 months, the median overall survival and progression-free survival were 102 and 48.8 months, respectively. In the multivariate analysis, the blastoid variant, an age ≥55 years, and a transplant comorbidity index ≥2 were independent predictors of survival.

Conclusions

>70% achieved prolonged survival. Blastoid morphology, age older than 55 years, and comorbidities diminished outcomes after transplantation.

查看原文本刊更多论文

阿根廷套细胞淋巴瘤患者自体干细胞移植的真实世界数据

背景：对于对诱导治疗有反应的套细胞淋巴瘤患者，自体造血祖细胞移植的一线巩固治疗仍然是一种标准治疗方法。然而，阿根廷这些患者的预后尚未完全确定。本文旨在描述与阿根廷套细胞淋巴瘤移植后患者生存率提高相关的因素。此外，还评估了移植后24个月内复发与总生存期之间的关系。方法采用回顾性、多中心研究。研究纳入了2007-2023年在阿根廷骨髓移植和细胞治疗小组（gatmoc - tc）附属中心接受自体造血祖细胞移植的18岁以上诊断为套细胞淋巴瘤的患者。对于生存分析，采用里程碑方法：总生存期从24个月内复发组的进展日期计算，从移植后24个月的里程碑计算。结果共纳入阿根廷9个中心166例患者，其中男性128例（77%）。移植时的中位年龄为58岁。18例（11%）具有囊胚形态。145例（87%）患者移植前完全缓解。中位随访时间为38.4个月，中位总生存期和无进展生存期分别为102个月和48.8个月。在多变量分析中，囊胚变异、年龄≥55岁、移植合并症指数≥2是生存的独立预测因素。囊胚形态、年龄大于55岁和合并症降低了移植后的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊